12 results about "Prolactin receptor" patented technology

The present disclosure provides antibodies or antigen-binding fragments thereof specific for prolactin receptor (PRLR). Such antibodies or antigen-binding fragments can be used in many pharmaceutical applications, for example, as anti-cancer agents and / or immune modulators. The present disclosure also concerns methods of making the antibodies or antigen-binding fragments described herein as well as compositions comprising such antibodies or antigen-binding fragments. The present disclosure further relates to nucleic acid molecules encoding such antibodies or antigen-binding fragments. In addition, the present disclosure provides therapeutic and / or diagnostic uses of such antibodies or antigen-binding fragments.

A method for producing a metabolism-activated liver organ, comprising a step for culturing primary hepatocytes or hepatocyte-like cells in a differential medium to obtain a metabolism-activated liver organ, the differential medium is a medium containing a glucocorticoid receptor agonist and one or two selected from the group consisting of a growth hormone receptor agonist and a prolactin receptor agonist.

The invention provides a mouse monoclonal antibody specifically combined with a prolactin receptor PRLR and application of the mouse monoclonal antibody. Specifically, the invention provides an antibody targeting PRLR or an antigen binding fragment thereof, and a heavy chain variable region of the antibody comprises the following complementarity determining regions CDR: VHCDR1-3 as shown in SEQ ID NO: 6-8; and the light chain variable region comprises the following complementarity determining regions CDR: VLCDR1 to VLCDR3 as shown in SEQ ID NO: 2 to SEQ ID NO: 4. The antibody provided by the invention can specifically recognize and bind to PRLR protein, can also bind to human-derived and monkey-derived PRLR antigens and inhibit the growth and / or proliferation of tumors or tumor cells, and can mediate internalization after binding to the PRLR protein expressed on the surfaces of the cells.

An antibody or antigen-binding fragment thereof binds to human prolactin (hPRL) whilst also neutralizing its agonism of the human PRL receptor (hPRLR). Advantageously, this allows other hPRLR agonists to continue signalling. In turn, the antibody or antigen-binding fragment thereof is suitable for therapeutic use, e.g., as a composition comprising the antibody or antigen-binding fragment thereof. For example, the antibody or antigen-binding fragment thereof may be for use in the treatment of a disease or condition which is modulated by PRL, e.g., for use in the treatment of pain.

The invention belongs to the technical field of biology, discloses a method for regulating the attack behavior of channa argus based on a prolactin PRL signal channel, provides a transcriptional regulation channel of an olfactory prolactin receptor (PRLR) for regulating the attack behavior of channa argus, and finds that a prl gene and caor24 olfactory receptor differential expression are screened from attack difference individuals before and after channa argus breeding. The transcriptional regulation and control effect of the snakehead PRL / PRLR / STAT5 signal channel on caor24 is verified. The method for regulating and controlling the attack behavior of the snakeheaded fish based on the PRL signal channel is established, and a new thought is provided for regulation and control of the attack behavior of the fish. The method provides a practical solution thought for aquaculture attack behavior regulation and control.

The invention relates to a prolactin receptor antibody and application thereof, in particular to a PRLR targeting antibody or an antigen binding fragment thereof, or a variant which has at least 85% sequence identity with the antibody or the antigen binding fragment thereof and retains PRLR binding activity thereof, and the antibody targets an extracellular fragment of a prolactin receptor. The antibodies of the invention bind to PRLR with high affinity.

The present invention relates to a prolactin receptor antibody and its applications, and more specifically to an antibody or its antigen-binding fragment that targets PRLR, or a variant that retains its PRLR-binding activity while having at least 85% sequence identity with the antibody or its antigen-binding fragment, wherein the antibody targets an extracellular segment that targets the prolactin receptor. The antibody of the present invention binds to PRLR with high affinity.

The invention relates to a prolactin receptor antibody and application thereof, in particular to a PRLR targeting antibody or an antigen binding fragment thereof, or a variant which has at least 85% sequence identity with the antibody or the antigen binding fragment thereof and retains PRLR binding activity thereof, and the antibody targets an extracellular fragment of a prolactin receptor. The antibodies of the invention bind to PRLR with high affinity.

The present invention provides an antibody capable of binding to a prolactin receptor PRLR and a use thereof. In particular, the present invention provides an antibody or an antigen binding fragment thereof targeting PRLR. The antibody provided by the invention can specifically recognize and bind to PRLR protein, can mediate internalization after binding to the PRLR protein expressed on the cell surface, and can bind to human and monkey PRLR antigens; the antibody and ADC of the present invention can be endocytosed by cells through PRLR receptors bound to the surfaces of the cells, thereby efficiently exerting the killing effect of ADC drugs in a targeting manner.

The antibody or its antigen-binding fragment binds to human prolactin (hPRL) while also neutralizing its agonism against the human PRL receptor (hPRLR). Advantageously, this allows other hPRLR agonists to continue signaling. As a result, this antibody or its antigen-binding fragment is suitable for therapeutic use, for example, as part of a composition containing the antibody or its antigen-binding fragment. For instance, the antibody or its antigen-binding fragment may be used in the treatment of diseases or conditions modulated by PRL, such as in the treatment of pain.

A method for producing a metabolically activated liver organoid, the method including culturing primary hepatocytes or hepatocyte-like cells in a differentiation medium to obtain a metabolically activated liver organoid, in which the differentiation medium is a medium including one or two selected from the group consisting of a growth hormone receptor agonist and a prolactin receptor agonist, and a glucocorticoid receptor agonist.